Thus, employing drugs already in clinical use, such as simvastatin, could offer a therapeutic strategy for decreasing bradykinin- and/or IL-1β-induced pulmonary edema in patients with COVID-19. This evidence concerns the gene KNG1 and pulmonary edema.